免疫检查点抑制剂与癌症患者的周围动脉疾病有关
Jason S Chwa1, Alexander T Hong1, Forest Lin2
1Keck School of Medicine, University of Southern California, Los Angeles, CA.
Journal of vascular surgery
|February 13, 2026
概括
免疫检查点抑制剂 (ICI) 与癌症患者,特别是患有血管疾病患者的外周动脉疾病 (PAD) 风险较高有关. 这强调了在接受ICI的患者中监测PAD的必要性.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗.
- 已知ICI的心血管风险,但它们与外周动脉疾病 (PAD) 的联系尚不清楚.
研究的目的:
- 为了研究ICI治疗与PAD,慢性肢体威胁性缺血症 (CLTI) 或癌症患者的下肢截肢 (LEA) 之间的关联.
主要方法:
- 使用TriNetX. 的回顾性多中心队列研究.
- 在66,766名ICI治疗患者和66,766名对照人群中,倾向性得分匹配 (1:1).
- 卡普兰-梅尔分析和考克斯模型评估了5年的结果,包括PAD,CLTI和LEA.
主要成果:
- 治疗ICI与PAD风险显著增加有关 (HR 1.59).
- 在所有ICI类 (PD-1,PD-L1,CTLA-4抑制剂) 中观察到增加PAD风险.
- 在高危患者中,ICI使用也增加了LEA的风险 (HR 1.85).
结论:
- 在癌症患者中,ICI治疗与PAD和LEA的风险增加有关.
- 患有先前存在的血管风险因素的患者特别容易受到伤害.
- 血管评估和监测对于接受ICI治疗的患者至关重要.
相关概念视频
Peripheral Artery Disease I: Introduction
400
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
400
Peripheral Artery Disease IV: Nursing Management
398
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
398
Peripheral Artery Disease III: Interprofessional Care
374
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
374
Peripheral Artery Disease V: Postoperative Nursing Management
426
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
426
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
461
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
461
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
630
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
630


